Clinical Trial Update: Subcutaneous Immunoglobulin (Hizentra) in Patients With Dermatomyositis: A Proof of Concept Study [EARLY_Phase 1]

View source ↗

Summary

An early-phase proof-of-concept trial of Hizentra (subcutaneous immunoglobulin) in dermatomyositis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis

Drugs mentioned

• Hizentra (subcutaneous immunoglobulin (IgG))

Snippet

Sponsor: Thomas Jefferson University | Conditions: Dermatomyositis | EARLY_Phase 1 | Status: TERMINATED